Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Thymosin Alpha-1 is clinically used in some countries as an immunomodulator for chronic hepatitis B/C and as an adjuvant in cancer therapy, enhancing cell-mediated immunity41487.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Thymosin Alpha-1 is a 28-amino-acid thymic peptide fragment of prothymosin alpha that activates dendritic cells and T cells primarily via TLR9/MyD88/NF-κB signaling, enhancing Th1 responses and NK-cell cytotoxicity414.
Liraglutide is 31 amino acids long, whereas Thymosin Alpha-1 is shorter as it has a length of 28 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. Thymosin Alpha-1 is made up of a sequence of Serine, Aspartic acid, Alanine, Alanine, Valine, Aspartic acid, Threonine, Serine, Serine, Glutamic acid, Isoleucine, Threonine, Threonine, Lysine, Aspartic acid, Leucine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Valine, Valine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine.
Liraglutide
GCG
Thymosin Alpha-1
PTMA